Investments & Funding

Originally set to expire on May 12, 2025, the tender offer is now extended to the end of the day on May 28, 2025, U.S. Eastern Daylight Time, according to a recent filing and announcements from the acquirer group.

Under the agreement, Alchemab will manage the initial clinical development through early Phase I trials, after which Lilly will take over later-stage development, regulatory approvals, and global commercialization.

Codix Bio is expected to reduce stockouts, lower testing costs, and improve healthcare outcomes, especially in rural and underserved communities, by producing rapid diagnostic kits locally.

The focus was on digital health, artificial intelligence, prevention, personalized and precision medicine, and longevity, marking a significant milestone in Abu Dhabi’s mission to advance health and well-being for all.

KKR already holds a 17% stake in Biotage through its life sciences platform, Gamma Biosciences, and would gain full control if the deal proceeds.

The new facility is designed to accelerate the development of next-generation ADCs, targeted therapies that combine antibodies with potent cytotoxic agents to precisely attack tumor cells while minimizing harm to healthy tissues.

Under the terms of the agreement, Lexicon will complete specific preclinical activities before handing over the reins to Novo Nordisk for further development, manufacturing, and commercialization.

Elevated levels of lipoprotein (a) are linked to a heightened risk of atherosclerotic cardiovascular disease, affecting approximately one in five adults worldwide, potentially leading to severe health problems, including heart attacks and strokes.

This substantial investment will primarily support the clinical advancement of AGT-100216, which inhibits the histone deacetylase 6 (HDAC6) enzyme implicated in neurodegeneration and aging-related processes at the cellular level.